Shares of Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twenty-two research firms that are currently covering the company, MarketBeat reports. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $20.29.
Several research firms recently issued reports on ARVN. BTIG Research set a $16.00 target price on Arvinas and gave the stock a "buy" rating in a research report on Friday, May 2nd. UBS Group dropped their price target on Arvinas from $74.00 to $21.00 and set a "buy" rating for the company in a research note on Thursday, May 15th. Leerink Partnrs lowered Arvinas from a "strong-buy" rating to a "hold" rating in a research note on Sunday, June 1st. Wells Fargo & Company dropped their price target on Arvinas from $26.00 to $19.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. Finally, Citigroup dropped their price target on Arvinas from $10.00 to $9.50 and set a "neutral" rating for the company in a research note on Monday, May 5th.
View Our Latest Research Report on ARVN
Arvinas Price Performance
Shares of NASDAQ:ARVN traded down $0.27 during trading on Tuesday, hitting $7.50. 703,055 shares of the company's stock were exchanged, compared to its average volume of 1,494,348. Arvinas has a 52-week low of $5.90 and a 52-week high of $31.28. The business's 50-day simple moving average is $7.29 and its 200 day simple moving average is $11.23. The company has a market cap of $547.06 million, a price-to-earnings ratio of -11.33 and a beta of 2.17.
Arvinas (NASDAQ:ARVN - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $2.07. Arvinas had a negative return on equity of 7.74% and a negative net margin of 10.92%. During the same quarter in the previous year, the company earned ($0.97) earnings per share. Arvinas's revenue for the quarter was up 646.2% on a year-over-year basis. On average, sell-side analysts anticipate that Arvinas will post -3.81 EPS for the current fiscal year.
Insider Buying and Selling at Arvinas
In other news, CFO Andrew Saik sold 5,700 shares of the stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $7.61, for a total value of $43,377.00. Following the sale, the chief financial officer directly owned 164,401 shares in the company, valued at approximately $1,251,091.61. This represents a 3.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 4.73% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Arvinas by 18.4% during the 1st quarter. Vanguard Group Inc. now owns 8,362,200 shares of the company's stock worth $58,703,000 after purchasing an additional 1,299,639 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Arvinas by 6.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,103,011 shares of the company's stock worth $78,656,000 after purchasing an additional 249,295 shares during the period. RTW Investments LP increased its holdings in Arvinas by 19.8% during the 4th quarter. RTW Investments LP now owns 3,334,308 shares of the company's stock worth $63,919,000 after purchasing an additional 551,979 shares during the period. T. Rowe Price Investment Management Inc. purchased a new position in Arvinas during the 4th quarter worth $42,332,000. Finally, Alyeska Investment Group L.P. purchased a new position in Arvinas during the 1st quarter worth $12,636,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors.
Arvinas Company Profile
(
Get Free ReportArvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Featured Articles

Before you consider Arvinas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arvinas wasn't on the list.
While Arvinas currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.